a Safety and Tolerability Study of EP-9001A in Healthy Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Nerve Growth Factor(NGF)plays an important role in the pathogenesis of neuropathic pain including cancer pain. EP-9001A is a humanized monoclonal antibody targeting NGF, thus thought to alleviate neuropathic pain though the blockade of NGF signal pathway. The primary objective of the study is to assess the safety and tolerability of a single dose of subcutaneous (SC) administered EP-9001A in healthy Chinese subjects.
Epistemonikos ID: a1f0cc554e12f06053204bf505a434a1fd02d02b
First added on: May 10, 2024